Pharmaceutical Technology on MSN
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...
TipRanks on MSN
Lantern Pharma presents clinical data from LP-284
Lantern Pharma (LTRN) announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & ...
The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has granted ...
Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...
Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...
A new review finds that chlorophyll and its derivatives may regulate blood sugar and mimic insulin, but safety risks and a lack of human trials mean the green pigment’s therapeutic potential is still ...
iSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan jDepartment of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan ...
May 22 (Reuters) - Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's (NOVOb.CO), opens new tab Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal ...
A large percentage of patients with type 2 diabetes enrolled in Medicaid have restricted access to sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback